Jack Wallace: Got it. That’s helpful. And then, Brent, this one is for you. The R&D list, it sounds like that’s ongoing and will continue through next year and probably ’25, you support the migration. Just thinking about the context of that spend relative to the ’25 targets. I say next year is going to be a little bit of an odd year with the revenue cadence on the TFC changes. But thinking about the percentage of revenue targets there, is that 17% to 18%, still a good target for the ’25 period?
Brent Bowman: So yes, we’re not going to provide future guidance right now, but we’re happy with the momentum and the execution, as Peter mentioned, growing at 18%. And we have our 2025 targets out there. tracking about a year ahead. And remember, that’s a run rate target. So we’re on track for that about a year ahead, and we’re pleased with the broad portfolio we have to execute against.
Operator: Your next question comes again from the line of Ken Wong with Oppenheimer.
Ken Wong : Lots of stuff spinning in my head right now. So maybe just back on the Vault CRM, would just love a sense of like any thoughts on how this could potentially impact pricing? Would that possibly change? And then second, just one for Brent on the impact of kind of the TFC that you called out at Investor Day, is that something that should hit at the start of the year for fiscal ’24? What’s the right way to think about when we should start rolling that impact in?
Paul Shawah : Ken, this is Paul. Yes, I’ll take the question on pricing. So the way to think about it is the licensing model and the pricing will all stay the same and all of the same add-ons that we have will also be available with Vault CRM. So nothing really changes there. It will be pretty seamless and easy for our customers.
Brent Bowman: And then on the termination for convenience, Ken. So yes, the $60 million is effective February 1 going forward. And how you should think about that is about 60% of that, we expect to have an impact Q1 of next year. And with the balance of that kind of diminishing over the balance of the year. And one other point there is it’s — the vast majority will be on the R&D Solutions side of the business. So it’s going well. We’re working with customers and we’re on track.
Operator: Your next question comes from the line of Brad Sills with Bank of America.
Brad Sills : I wanted to ask about the new hires. You mentioned 483 new hires this quarter. Just curious where are the areas where you’re focusing on new hires from a product standpoint and R&D versus sales and marketing, please?
Peter Gassner: Yes. I believe that was 483 net additions in the quarter. It’s really broad-based. It’s is true, right? If you look at our account executives, our account partners, it’s there. It’s in our engineering, our product management, our services team, our support team I think the area where the growth is a bit lower in the G&A. We have a pretty efficient model there. So it’s customer-facing and product-facing people is where the growth is.
Brad Sills : One more, if I may, please. Outside life sciences verticals, not something you’ve talked about a whole lot here at the Analyst Day and here, just any update on where you are with those verticals? And is — could that be an increasing focus going forward, or are you still very much in that kind of early reference selling approach?
